IM
The startup develops a triple-drug gel formulation that modifies levodopa metabolism, enhancing its effectiveness in treating advanced Parkinson's disease. This treatment utilizes a lightweight infusion pump to deliver medication directly into the small intestine, ensuring consistent dosing and minimizing gastrointestinal side effects.
Updated 3 months ago
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a triple-drug gel formulation that modifies levodopa metabolism, enhancing its effectiveness in treating advanced Parkinson's disease. This treatment utilizes a lightweight infusion pump to deliver medication directly into the small intestine, ensuring consistent dosing and minimizing gastrointestinal side effects.